Trial Profile
A Phase II Trial of Alimta (Pemetrexed) in Patients With Recurrent Malignant Gliomas, Primary Central Nervous System Lymphoma, and Brain Metastases
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Dec 2022
Price :
$35
*
At a glance
- Drugs Pemetrexed (Primary)
- Indications Brain metastases; Cancer metastases; CNS cancer; Glioma; Lymphoma; Solid tumours
- Focus Therapeutic Use
- 04 Mar 2020 Planned End Date changed from 1 Dec 2020 to 1 Dec 2022.
- 04 Mar 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2022.
- 05 Apr 2019 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.